Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum A Case Series and Literature Review

Department of Dermatology, University of California at San Francisco, CA, USA.
Archives of dermatology (Impact Factor: 4.79). 11/2010; 146(11):1265-70. DOI: 10.1001/archdermatol.2010.328
Source: PubMed


Hidradenitis suppurativa (HS) and pyoderma gangrenosum (PG) are both rare inflammatory skin conditions that are associated with systemic inflammatory diseases. We performed a retrospective medical chart review of patients with an overlap of HS and PG.
We identified 11 cases of PG lesions presenting in patients with HS. Ten of the patients were women, and 9 were obese. All the patients developed HS lesions first, a median of 2.5 years (range, 0-15 years) preceding the appearance of PG lesions. All patients required multiple therapeutic agents because their diseases were often poorly responsive to standard therapies. Two patients received tumor necrosis factor inhibitors; 1 responded to treatment. One patient was treated with anakinra (interleukin-1 receptor antagonist) and had a 75% improvement of her lesions.
We have identified a group of patients who have an overlap of PG and HS. Pyoderma gangrenosum can appear at any point after the development of HS and often has a severe, refractory course. We propose that PG and HS may represent variant manifestations of cytokine dysregulation by the innate immune system with common etiology. New therapeutic agents are eagerly sought, and further investigation with regard to interleukin 1 blockade is warranted.

Download full-text


Available from: Richard joseph Antaya, Dec 09, 2014
  • Source
    • "Reactive arthritis can develop as a possible complication of AI.[40] Synovitis, acne pustulosis, hyperostosis, and osteitis (SAPHO)-syndrome has been described in AI patients.[46] Pyoderma gangrenosum is another complication in AI patients unresponsive to various treatments.[47] Secondary amyloid A amyloidosis has been observed occasionally with multi-systemic manifestations including renal and heart affection.[48] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acne inversa (AI) is a disabilitating chronic inflammatory disease with major negative impact on quality of life and significant co-morbidities. This is an important link to insights into immune dysfunction, which stimulated therapeutic approaches like tumor necrosis-α inhibitor therapy. This new off-label drug treatment is particularly beneficial when used in combination with wide excision of inflamed skin and subcutaneous tissue. Retinoids have been reported to be helpful in secondary prevention. The standard of therapy in advanced cases is surgery with wide excisions and healing by secondary intention. This treatment results in significant reduction of complaints and achieves satisfactory body contouring.
    Full-text · Article · Mar 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hidradenitis suppurativa, or Verneuil's disease, is common, especially in women, but it is often undiagnosed. Clinical manifestations include painful nodules, abscesses, sinus tracts, and rope-like hypertrophic scars in the apocrine gland-bearing areas (axillae, groins, genitals, perianal area). It is a chronic and severe disease. Smoking and obesity are risk factors, but its cause is unknown: it is a disease of the follicular apparatus, neither infectious nor hormonal. Severe dramatic forms are rare. Quality of life is severely affected, even in the mild forms. Treatment is both medical and surgical: wide-spectrum antibiotics and excisions tailored to the extent of involvement. Anti-TNF-α agents are moderately effective; their risk–benefit ratio is still in question. Laser treatment is under study. Spondylarthropathies in the setting of Crohn's disease, as an association, or isolated can also be a diagnostic feature of Verneuil's disease, and can occur during disease flares.
    No preview · Article · Jun 2011 · Revue du Rhumatisme Monographies
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease. Since current treatments are unsatisfactory for many patients, there is a high need for effective drugs for this debilitating disease. Recent pathogenic insights suggest inflammasome activation and IL-1β production are important in HS. Colchicine is efficacious in the IL-1β- and inflammasome-mediated diseases gout, familial Mediterranean fever and Behçet's disease, and therefore a potentially effective drug in HS. To investigate the efficacy of colchicine in HS. Methods: In an open prospective pilot study, 8 HS patients were treated with the accepted gout maintenance regimen of 0.5 mg colchicine b.i.d. orally up to 4 months. Efficacy was assessed by a physician global assessment. Colchicine treatment did not result in a clinically relevant improvement of disease severity. Three patients experienced nausea and diarrhea as known side effects. Colchicine in the used dose regimen does not ameliorate HS severity.
    No preview · Article · Nov 2011 · Dermatology
Show more